Skip to content

Halozyme Therapeutics

US · HALO #1276 by market cap Listed 1970
91.35 -1.69 -1.82%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

About Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Founded
1998
CEO
Dr. Helen I. Torley, M.R.C.P.,MB.Ch.B.
Employees
423
Headquarters
San Diego, California, United States of America
Fiscal year end
12-31
Website
halozyme.com

Company profile

Exchange
US
Symbol
HALO
Market-cap rank
#1276
Listing date
1970-01-01
Market cap
10.41B
Float cap
10.30B
Shares out
114.01M
Float shares
112.71M

Sectors & themes

Biotechnology Best Growth Stocks Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.

Halozyme Therapeutics discussion 0 comments

Add a comment